1. Home
  2. AARD vs NRXP Comparison

AARD vs NRXP Comparison

Compare AARD & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aardvark Therapeutics Inc.

AARD

Aardvark Therapeutics Inc.

HOLD

Current Price

$5.41

Market Cap

107.7M

Sector

Health Care

ML Signal

HOLD

Logo NRX Pharmaceuticals Inc.

NRXP

NRX Pharmaceuticals Inc.

HOLD

Current Price

$3.37

Market Cap

151.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AARD
NRXP
Founded
2017
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.7M
151.1M
IPO Year
2025
2017

Fundamental Metrics

Financial Performance
Metric
AARD
NRXP
Price
$5.41
$3.37
Analyst Decision
Buy
Strong Buy
Analyst Count
9
4
Target Price
$15.29
$38.25
AVG Volume (30 Days)
134.1K
635.1K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
43.11
69.70
EPS
N/A
N/A
Revenue
N/A
$1,225,000.00
Revenue This Year
N/A
$2,547.84
Revenue Next Year
N/A
$1,591.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.35
$1.65
52 Week High
$17.94
$5.06

Technical Indicators

Market Signals
Indicator
AARD
NRXP
Relative Strength Index (RSI) 44.85 45.64
Support Level $4.91 $3.09
Resistance Level $6.01 $3.50
Average True Range (ATR) 0.59 0.14
MACD -0.03 -0.00
Stochastic Oscillator 47.51 47.19

Price Performance

Historical Comparison
AARD
NRXP

About AARD Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Share on Social Networks: